| 國立成功大學 |
2008-07-28 |
Gelsolin表現對基因剔除鼠之病理表現型與腫瘤發展之影響
|
張佑民; Chang, You-Min |
| 東方設計學院 |
2008-12-18 |
GEL推理複雜性檢核表之初探
|
許照紅; 許德發; 許瑞珍; 吳淨淩; (東方技術學院食品科技系) |
| 東方設計學院 |
2008-12 |
GEL推理複雜性檢核表之初探
|
許照紅; 許德發; 許瑞珍; 吳淨淩; (東方技術學院食品科技系); (東方技術學院化妝品應用與管理系) |
| 國立成功大學 |
1976-05 |
GEM-ACV及水裙之種類
|
馮小川 |
| 國立交通大學 |
2014-12-08T15:42:08Z |
GEM: A Gaussian evolutionary method for predicting protein side-chain conformations
|
Yang, JM; Tsai, CH; Hwang, MJ; Tsai, HK; Hwang, JK; Kao, CY |
| 國立臺灣大學 |
2002 |
GEM: A Gaussian evolutionary method for predicting protein side-chain conformations
|
Yang, Jinn-Moon; Tsai, Chi-Hung; Hwang, Ming-Jing; Tsai, Huai-Kuang; Hwang, Jenn-Kang; Kao, Cheng-Yan |
| 國立臺灣海洋大學 |
2002 |
GEM: a Gaussian Evolutionary Method for predicting protein side-chain conformations
|
Jinn-Moon Yang; Chi-Hung Tsai; Ming-Jing Hwang; Huai-Kuang Tsai; Jenn-Kang Hwang; Cheng-Yan Kao |
| 國立交通大學 |
2014-12-08T15:21:02Z |
GemAffinity: A Scoring Function for Predicting Binding Affinity and Virtual Screening
|
Hsu, Kai-Cheng; Chen, Yen-Fu; Yang, Jinn-Moon |
| 國立交通大學 |
2014-12-08T15:22:08Z |
GemAffinity: a scoring function for predicting binding affinity and Virtual Screening
|
Hsu, Kai-Cheng; Chen, Yen-Fu; Yang, Jinn-Moon |
| 中華大學 |
1998 |
GEMCAB：一個對於可測試性設計的性能標桿電路
|
趙智德; Zhao, Zhi De |
| 臺北醫學大學 |
2005 |
Gemcitabine /Carboplatin chemotherapy for Pure Small Cell Carcinoma of Prostate
|
陳冠州; Chen KC; Chiu AW; Chiang HS; Chu JS; Cheng CJ; |
| 國立臺灣大學 |
2002 |
Gemcitabine and Cisplatin in a Multimodality Treatment for Locally Advanced Non-Small Cell Lung Cancer
|
楊志新; 李元麒; 雷德; 許駿; 鄭安理; 陳育民; 陸坤泰; 彭瑞鵬; 楊泮池; YANG, CHIH-HSIN; LEE, YUNG-CHIE; LUI, LOUIS TAK; HSU, CHIUN; CHENG, ANN-LII; CHEN, YU-MING; LUH, KWEN-TAY; PENG, JUI-PENG; YANG, PAN-CHYR |
| 臺大學術典藏 |
2020-05-26T09:27:31Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Perng R.-P.; Chih-Hsin Yang;Tsai C.M;Wang L.S;Lee Y.C;Chang C.J;Lui L.T;Yen S.H;Hsu C;Cheng A.L;Liu M.Y;Chiang S.C;Chen Y.M;Luh K.T;Huang M.H;Yang P.-C;Perng R.-P.; CHIH-HSIN YANG; Tsai C.M; Wang L.S; Lee Y.C; Chang C.J; Lui L.T; Yen S.H; Hsu C; Cheng A.L; Liu M.Y; Chiang S.C; Chen Y.M; Luh K.T; Huang M.H; Yang P.-C |
| 臺大學術典藏 |
2020-04-10T12:51:31Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.;Tsai C.M.;Wang L.S.;Lee Y.C.;Chang C.J.;Lui L.T.;Yen S.H.;Chiun Hsu;Cheng A.L.;Liu M.Y.;Chiang S.C.;Chen Y.M.;Luh K.T.;Huang M.H.;Yang P.-C.;Perng R.-P.; Perng R.-P.; Yang P.-C.; Luh K.T.; Huang M.H.; Chen Y.M.; Chiang S.C.; Liu M.Y.; Cheng A.L.; Chiun Hsu; Tsai C.M.; Wang L.S.; Lee Y.C.; Chang C.J.; Lui L.T.; Yen S.H.; Yang C.H. |
| 臺大學術典藏 |
2020-12-02T02:36:06Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.;Tsai C.M.;Wang L.S.;Lee Y.C.;Chang C.J.;Lui L.T.;Yen S.H.;Hsu C.;Cheng A.L.;Liu M.Y.;Chiang S.C.;Chen Y.M.;Luh K.T.;Huang M.H.;Pan-Chyr Yang;Perng R.-P.; Yang C.H.; PAN-CHYR YANG |
| 臺大學術典藏 |
2021-05-26T03:35:12Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.; Tsai C.M.; Wang L.S.; Lee Y.C.; Chang C.J.; Lui L.T.; Yen S.H.; Hsu C.; Cheng A.L.; Liu M.Y.; Chiang S.C.; Chen Y.M.; KWEN-TAY LUH; Huang M.H.; Yang P.-C.; Perng R.-P. |
| 臺大學術典藏 |
2021-09-01T02:02:28Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.; Tsai C.M.; Wang L.S.; Lee Y.C.; Chang C.J.; Lui L.T.; Yen S.H.; Hsu C.; ANN-LII CHENG; Liu M.Y.; Chiang S.C.; Chen Y.M.; Luh K.T.; Huang M.H.; Yang P.-C.; Perng R.-P. |
| 國立臺灣大學 |
2007 |
Gemcitabine and Ifosfamide as a Second-Line Treatment for Cisplatin- Refractory Metastatic Urothelial Carcinoma: A Phase Ii Study
|
林家齊; 徐志宏; 黃昭淵; 耿孝宜; 蔡育傑; 黃國皓; 鄭安理; 蒲永孝; LIN, CHIA-CHI; HSU, CHIH-HUNG; HUANG, CHAO-YUAN; KENG, HSIAO-YI; TSAI, YU-CHIEH; HUANG, KUO-HOW; CHENG, ANN-LII; PU, YEONG-SHIAU |
| 國立臺灣大學 |
2007-04 |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study
|
Lin, Chia-Chi; Chih-Hung; Hsu; Huang, Chao-Yuan; Keng, Hsiao-Yi; Tsai, Yu-Chieh; Huang, Kuo-How; Cheng, Ann-Lii; Pu, Yeong-Shiau |
| 臺大學術典藏 |
2018-09-10T06:13:47Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin, Chia-Chi;Chih-Hung;Hsu;Huang, Chao-Yuan;Keng, Hsiao-Yi;Tsai, Yu-Chieh;Huang, Kuo-How;Cheng, Ann-Lii;Pu, Yeong-Shiau; Lin, C.-C. and Hsu, C.-H. and Huang, C.-Y. and Keng, H.-Y. and Tsai, Y.-C. and Huang, K.-H. and Cheng, A.-L. and Pu, Y.-S.; Lin, Chia-Chi; CHAO-YUAN HUANG; CHIH-HUNG HSU; Chih-Hung; Hsu; KUO-HOW HUANG; YU-CHIEH TSAI; Huang, Chao-Yuan; ANN-LII CHENG; Keng, Hsiao-Yi; Tsai, Yu-Chieh; YEONG-SHIAU PU; Huang, Kuo-How; Cheng, Ann-Lii; Pu, Yeong-Shiau |
| 臺大學術典藏 |
2020-05-25T07:35:33Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Chia-Chi Lin; Hsu C.-H; Huang C.-Y; Keng H.-Y; Tsai Y.-C; Huang K.-H; Cheng A.-L; Pu Y.-S. |
| 臺大學術典藏 |
2021-01-28T02:03:54Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; KUO-HOW HUANG; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-03-04T02:36:02Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Keng H.-Y.;Yu-Chieh Tsai;Huang K.-H.;Cheng A.-L.;Pu Y.-S.; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; YU-CHIEH TSAI; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:33Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-10-14T02:46:15Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.; Hsu C.-H.; CHAO-YUAN HUANG; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-02-02T00:46:57Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Keng H.-Y.;Tsai Y.-C.;Huang K.-H.;Cheng A.-L.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2022-09-15T01:09:54Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Chia-Chi Lin; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 國家衛生研究院 |
2015-10 |
Gemcitabine enhances antitumor efficacy of recombinant lipoimmunogen-based immunotherapy
|
Chang, LS;Yan, WL;Chang, YW;Yeh, YC;Chen, HW;Leng, CH;Liu, SJ |
| 國立臺灣大學 |
2007 |
Gemcitabine Is Preferentially Chemosensitive in Cyclin D1 or Cyclin E over-Expressing Human Gastric Cancer Cells
|
沈盈君; 鄭安理; SHEN, YING-CHUN; CHENG, ANN-LII |
| 國家衛生研究院 |
2015-07 |
Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review
|
Park, JO;Oh, DY;Hsu, C;Chen, JS;Chen, LT;Orlando, M;Kim, JS;Lim, HY |
| 臺大學術典藏 |
2022-08-19T00:20:46Z |
Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review
|
Lim H.Y.; Kim J.S.; Orlando M.; Chen L.-T.; Chen J.-S.; CHIUN HSU; Oh D.-Y.; Park J.O. |
| 臺大學術典藏 |
2015 |
Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review
|
Oh D.-Y.; Chiun Hsu; Chen J.-S.; Chen L.-T.; Orlando M.; Kim J.S.; Lim H.Y.; Park J.O.; Park J.O.;Oh D.-Y.;Chiun Hsu;Chen J.-S.;Chen L.-T.;Orlando M.;Kim J.S.;Lim H.Y. |
| 臺大學術典藏 |
2021-01-28T01:06:31Z |
Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: A multicenter prospective Phase II trial
|
Hsieh J.C.; Hsu C.-L.; Ng S.-H.; Wang C.-H.; Lee K.-D.; Lu C.-H.; Chang Y.-F.; Hsieh R.-K.; KUN-HUEI YEH; Hsiao C.-H.; Chen S.-Y.; Shiau C.-Y.; Wang H.-M. |
| 國家衛生研究院 |
2008-12 |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu, C;Kuo, SH;Hu, FC;Cheng, AL;Shih, JY;Yu, CJ;Lin, CC;Huang, TC;Yang, PC;Yang, CH |
| 臺大學術典藏 |
2022-08-19T00:21:07Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
CHIUN HSU; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 國立臺灣大學 |
2008 |
Gemcitabine Plus Conventional-Dose Epirubicin Versus Gemcitabine Plus Cisplatin as First-Line Chemotherapy for Stage Iiib/Iv Non-Small Cell Lung Carcinoma-a Randomized Phase Ii Trial
|
許駿; 郭頌鑫; 胡賦强; 鄭安理; 施金元; 余忠仁; 林家齊; 楊泮池; 楊志新; HSU, CHIUN; KUO, SUNG-HSIN; HU, FU-CHANG; CHENG, ANN-LII; SHIH, JIN-YUAN; YU, CHONG-JEN; LIN, CHIA-CHI; YANG, PAN-CHYR; YANG, CHIH-HSIN |
| 臺大學術典藏 |
2020-04-10T12:51:22Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Huang T.-C.; Yang P.-C.; Yang C.-H.; Lin C.-C.; Chiun Hsu; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T07:35:30Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C; Kuo S.-H; Hu F.-C; Cheng A.-L; Shih J.-Y; Yu C.-J; Chia-Chi Lin; Huang T.-C; Yang P.-C; Yang C.-H. |
| 臺大學術典藏 |
2020-05-26T09:27:21Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Lin C.-C; Huang T.-C; Yang P.-C; CHIH-HSIN YANG; Yu C.-J; Shih J.-Y; Cheng A.-L; Hu F.-C; Kuo S.-H; Hsu C; Chih-Hsin Yang;Yang P.-C;Huang T.-C;Lin C.-C;Yu C.-J;Shih J.-Y;Cheng A.-L;Hu F.-C;Kuo S.-H;Hsu C |
| 臺大學術典藏 |
2020-08-13T06:33:59Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Yang C.-H.; Yang P.-C.; Huang T.-C.; Lin C.-C.; Yu C.-J.; Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2020-12-02T02:34:30Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; PAN-CHYR YANG; Yang C.-H. |
| 臺大學術典藏 |
2021-02-23T08:26:37Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; SUNG-HSIN KUO; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:26Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; ANN-LII CHENG; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-06-27T07:07:53Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; CHONG-JEN YU; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2018-09-10T06:52:59Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma—A randomized phase II trial
|
Chiun Hsu and Sung-Hsin Kuo and Fu-Chang Hu and Ann-Lii Cheng and Jin-Yuan Shih and Chong-Jen Yu and Chia-Chi Lin and Tsu-Chen Huang and Pan-Chyr Yang and Chih-Hsin Yang; Chong-Jen Yu; Sung-Hsin Kuo; JIN-YUAN SHIH; ANN-LII CHENG |
| 國家衛生研究院 |
2015-11 |
Gemcitabine synergistically enhances anti-tumor effects of recombinant immunogen-based cancer immunotherapy
|
Liu, SJ;Chang, LS;Yan, WL;Yeh, YC;Leng, CH |
| 國家衛生研究院 |
1997-05 |
Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study
|
Perng, RP; Chen, YM; MingLiu, J; Tsai, CM; Lin, WC; Yang, KY; WhangPeng, J |
| 臺大學術典藏 |
2021-08-10T03:53:07Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
SHIH-HUNG YANG; Lin Z.-Z.; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-09-01T01:54:20Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
Yang S.-H.; Lin Z.-Z.; Kuo S.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2022-06-10T06:11:13Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
Yang S.-H.; ZHONG-ZHE LIN; Kuo S.-H.; Cheng A.-L. |
